ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Sunday, October 21, 2018

9:00AM-11:00AM
Abstract Number: 153
Chemotaxis of Vδ2 T Cells to the Joints Contributes to the Pathogenesis of Rheumatoid Arthritis
T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 529
Chest Computed Tomography Abnormalities in Patients with Rheumatoid Arthritis By Serologic Status
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 673
Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment
9:00AM-11:00AM
Abstract Number: 73
Circular RNAs Expression Profile in Chinese Rheumatoid Arthritis Patients at Different Disease Activity
Rheumatoid Arthritis – Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 25
Circulating CD24hiCD38hi Regulatory B-Cells Influence Th17-Cell Responses in Patients with Granulomatosis with Polyangiitis
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 205
Circulating Plasma Metabolites and Risk of Rheumatoid Arthritis in the Nurses Health Study
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 94
Circulating Soluble MICA Is Associated to Lupus Nephritis and to a TLR/IFN-I Signature in T Cells in a Cohort of Adult SLE Patients
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 19
Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 45
CKD-506, First-in-Class Histone Deacetylase (HDAC) 6 Inhibitor, Ameliorates Rheumatoid Arthritis through Regulation of Inflammation and T Cell Function
Rheumatoid Arthritis – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 815
Classic and Atypical Polymyalgia Rheumatica, Are Different Syndromes? Study of 93 Patients with PET/CT from a Single Center
Vasculitis Poster I: Non-ANCA-Associated and Related Disorders
9:00AM-11:00AM
Abstract Number: 788
Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis
Systemic Sclerosis and Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 607
Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology
9:00AM-11:00AM
Abstract Number: 165
Clinical and Immunological Features of Antiphospholipid Syndrome in the Elderly: A Retrospective National Multicenter Study
Antiphospholipid Syndrome Poster
9:00AM-11:00AM
Abstract Number: 161
Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Antiphospholipid Syndrome Poster
9:00AM-11:00AM
Abstract Number: 569
Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 67
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology